Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mita Manna has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 19 November 2026
    • Published by MDPI AG in Current Oncology
      • Vol. 33  (11) , 718
      • https://doi.org/10.3390/curroncol33110718
    Open Access

    Lung Cancer Multidisciplinary Team Meetings in Canada: Current Practices and Expert Panel Recommendations

    by Marcio M. Gomes, David E. Dawe, Houda Bahig, Sophie Burelle, Christian Finley, Desirée Hao, Scott Johnson, Eugene Leung, Mita Manna, Renelle Myers, et al.

    Multidisciplinary team meetings (MDTMs) support coordinated lung cancer care, but Canada lacks national lung-cancer-specific guidance on their structure and processes. We conducted a quality-improvement initiative in which an expert panel adapted international good practices for lung cancer MDTMs to the Canadian context. Fourteen purposively selected healthcare professionals completed an electronic questionnaire describing 14 MDTMs and participated in semi-structured interviews, while one patient representative provided a separate perspective. Findings informed draft recommendations, which were rated electronically before an in-person workshop, refined at the workshop, and approved by all 15 participants. Key variations observed included that only 7 of 14 respondents reported mechanisms to promote participation by every profession, and MDT coordinators always or often attended meetings in 4 of 14 MDTMs. Identified shared challenges include inconsistent representation of core disciplines, variable access to unified electronic patient records, and non-standardized documentation. The panel agreed on 13 recommendations and four statements on the perceived value of MDTMs. The recommendations are deliberately kept general and flexible, to allow adaptation to provincial and local resources, organization, and culture. These recommendations and statements can support MDT consistency, communication, and patient-centred care.

  • Open Access

    Developing Care Networks for Young Women with Breast Cancer: Closing the Survivorship Gap During and After Endocrine Therapy

    by Rowen Greene, Mita Manna, Nathalie Levasseur

    Endocrine therapy is widely utilized for hormone receptor-positive breast cancer and is accompanied by significant side effects for premenopausal patients. The duration of therapy may extend up to 10 years, requiring patients and their families to undergo lasting adaptations to their way of life. During the early course of adjustment to therapy, a core set of interventions is indicated to address short-term impacts of therapy and maintain adherence. In the long term, early preventative health care is also indicated to manage cardiovascular and bone health into the survivorship period. Addressing this breadth of short- and long-term care needs for premenopausal breast cancer survivors necessitates intervention from an array of health care providers. Furthermore, the survivorship needs of each patient can be highly individualized, requiring a unique set of expertise to maintain adherence and long-term wellbeing. With the implementation of standardized, multidisciplinary follow-up for premenopausal hormone receptor-positive breast cancer survivors, transitions of care may be completed in a way that optimizes timely delivery of programming and clearly outlines the roles of each provider in the provision of high-quality care.

  • Open Access

    Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025

    by Christine Simmons, Omar F. Khan, Christine Brezden-Masley, David W. Cescon, Anil Abraham Joy, Nathalie LeVasseur, Katarzyna J. Jerzak, Karen A. Gelmon, Sandeep Sehdev, Stephen Chia, et al.

    Triple-negative breast cancer (TNBC) has been associated with a poorer prognosis than other subtypes, due to its more aggressive behaviour. Since 2020, significant advances in locoregional and systemic therapy have improved outcomes for patients with TNBC, but the implementation of these treatments remains inconsistent across Canada. There is, therefore, a critical need for evidence-informed, consensus-driven guidance to support the integration of new therapies into practice. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a pan-Canadian group of breast cancer specialists and Breast Cancer Canada, a patient advocacy organization, convened to develop national clinical consensus recommendations for the management of breast cancer. Through a selective literature review and modified Delphi process of national experts in the fields of medical oncology, radiation oncology, surgical oncology and pharmacy, REAL Alliance developed national consensus recommendations for the management of TNBC. The result is a set of 23 recommendations: four overall general recommendations, 11 in early-stage TNBC, and eight in metastatic TNBC. These recommendations are intended for oncology healthcare professionals, and are intended to guide evidence-informed, consistent care across Canada.

  • Open Access

    Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)

    by Aalok Kumar, Katarzyna J. Jerzak, Karen A. Gelmon, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley, Jeffrey Q. Cao, David W. Cescon, Stephen Chia, Scott Edwards, et al.

    Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype associated with a poor prognosis when not optimally treated. Over the past year, major advances—including results from DESTINY-Breast05, DESTINY-Breast09, DESTINY-Breast11, PATINA, and long-term APHINITY follow-up—have changed the treatment landscape regarding the place in therapy of antibody–drug conjugates and the optimal sequencing of systemic therapies. These developments prompted the need for updated evidence-informed consensus recommendations to support consistent, high-quality care across Canada. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), comprising clinical-academic oncologists from across Canada and Breast Cancer Canada, updated its 2024 HER2+ recommendations through a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% agreement. This 2025 update incorporates new data in early-stage, metastatic, and central nervous system-involved disease, including revisions to neoadjuvant and adjuvant treatment pathways and expanded guidance on the clinical use of antibody–drug conjugates.

  • Open Access

    Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Early Breast Cancer 2025

    by Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley, Jeffrey Q. Cao, David W. Cescon, Stephen Chia, Scott Edwards, Karen A. Gelmon, et al.

    Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) early breast cancer (EBC) is the most common breast cancer subtype and encompasses a biologically heterogeneous group of tumours. Endocrine therapy (ET) remains the cornerstone of treatment, but decisions regarding chemotherapy, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, and bone-modifying agents must be tailored to tumour biology, clinical stage, and menopausal status. REAL Canadian Breast Cancer Alliance (REAL Alliance), a pan-Canadian group of breast cancer specialists, convened to develop national clinical consensus recommendations for the systemic management of HR+/HER2− EBC. Using a structured consensus process, 28 recommendations were endorsed, spanning neoadjuvant and adjuvant systemic therapy, surgical considerations, and use of bisphosphonates. Key recommendations include the selective use of neoadjuvant chemotherapy for high-risk or locally advanced disease; genomic testing to guide chemotherapy decisions, particularly in postmenopausal patients; ET as the foundation of adjuvant therapy with intensification using CDK4/6 inhibitors in higher-risk patients; and adjuvant bisphosphonates in postmenopausal women to reduce recurrence and improve survival. These consensus recommendations provide practical, evidence-based guidance to support individualized, patient-centred management of HR+/HER2− EBC in the Canadian context.


  • Open Access

    Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025

    by Katarzyna J. Jerzak, Aalok Kumar, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley, Jeffrey Q. Cao, David W. Cescon, Stephen Chia, Scott Edwards, Anil Abraham Joy, et al.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer accounts for approximately two-thirds of all breast cancers. The treatment landscape for HR+/HER2− metastatic breast cancer has evolved in recent years, with multiple new therapies demonstrating clinical efficacy and improved patient outcomes. To provide evidence-informed guidance on best practices in the management of patients with HR+/HER2− metastatic breast cancer in Canada, consensus recommendations were developed by Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a standing nucleus committee with both clinical–academic oncologists from across Canada and representatives from Breast Cancer Canada, a patient advocacy organization. Recommendations were generated using a modified Delphi approach involving up to three anonymous voting rounds, with a predefined consensus threshold of 75%. These consensus recommendations offer guidance on optimal therapeutic strategies for HR+/HER2− metastatic breast cancer within the Canadian landscape, including integration of precision oncology and targeted therapies, optimal sequencing of therapies, and the importance of balancing the benefits of treatments with patient quality of life and preferences.


  • Open Access

    A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer

    by Saqib Raza Khan, Enxhi Kotrri, Daniel Breadner, Vijayananda Kundapur, Mita Manna

    The management strategies in resectable non-small cell lung cancer (NSCLC) have changed over the last few years. Despite advancements in surgical techniques and conventional chemotherapy, patients with resectable NSCLC remained at high risk of future recurrence. Clinical trials have demonstrated improvements in response rates, pathological outcomes, and survival with the perioperative approach. Considering the findings of these landmark trials, there is a pressing need to contextualize and incorporate these global developments into the national practice framework. This review outlines key developments from recent clinical trials, with a focus on perioperative strategies in early-stage operable NSCLC from a Canadian perspective. We discuss the integration of checkpoint inhibitors in the perioperative setting for patients without actionable genomic alterations, adjuvant targeted therapies for EGFR and ALK mutant disease, and emerging tools such as ctDNA based minimal residual disease monitoring. The article also addresses the practical challenges of implementing these advances within the Canadian healthcare system, including systemic therapy approvals, barriers, and importance of multidisciplinary care to guide clinicians in optimizing patient outcomes.


  • Open Access

    Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers

    by Angela Chan, Nancy Nixon, Muna Al-Khaifi, Alain Bestavros, Christine Blyth, Winson Y. Cheung, Caroline Hamm, Thomas Joly-Mischlich, Mita Manna, Tom McFarlane, et al.

    The adjuvant treatment landscape for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer (EBC) is rapidly evolving, with a diverse range of therapeutic options—including endocrine therapies, bisphosphonates, ovarian function suppression, olaparib, CDK4/6 inhibitors, and emerging agents such as immunotherapy. While these advances have markedly improved patient outcomes, they also introduce challenges related to implementation, monitoring, and resource allocation. Notably, therapies like CDK4/6 inhibitors require particularly close monitoring, creating logistical and capacity challenges for medical oncologists, whose workloads are already stretched due to rising cancer incidence and treatment complexities. These challenges underscore the need for innovative care delivery solutions to ensure patients with EBC continue to receive optimal care. This paper offers a comprehensive guide—a playbook—of multidisciplinary-team-based care models designed to optimize adjuvant treatment delivery in EBC. Drawing on real-world evidence and successful applications across Canadian centers, we explore models led by nurses, nurse practitioners (NPs), general practitioners in oncology (GPO), and pharmacists. Each model leverages the unique expertise of its team to manage treatment toxicities, facilitate adherence, and enhance patient education, thereby promoting effective and sustainable care delivery. Importantly, these models are not intended to compete with one another, but rather to serve as a flexible recipe book from which breast cancer care teams can draw strategies tailored to their local resources and patient needs. By detailing implementation strategies, benefits, and challenges—in many instances supported by quantitative metrics and economic evaluations—this work aims to inspire care teams nationwide to optimize the adjuvant management of patients with HR+, HER2– EBC.


  • Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study

    by Erika Arnold, Devin Laubscher, Huzaifa Saeed, Osama Ahmed, Ayesha Bashir, Haji Chalchal, Gary Groot, Duc Le, Mita Manna, Pamela Meiers, et al.

    PURPOSE: Breast cancer is uncommon in adolescent and young adult (AYA) women, accounting for approximately 1.8% of all breast cancers. There is a risk of delayed diagnosis of breast cancer among AYA women, especially among those residing in rural areas. The aim of this study was to assess the outcomes of AYA women for breast cancer in relation to rural residence. METHODS: This cohort study evaluated all women aged 35 years and younger with histologically confirmed breast cancer diagnosed between 2000 and 2019 in a Canadian province. A multivariate Cox proportional hazards model was used to assess the prognostic significance of rural residence and other variables for overall survival (OS) across all stages and disease-free survival in early-stage breast cancer. RESULTS: A total of 248 eligible AYA women with a median age of 32 years were identified, of whom 24% were younger than 30 years. Of all patients, 51% had node-positive disease, and 11% had stage IV disease at diagnosis. Among those with invasive breast cancer, 45% had hormone receptor–positive and human epidermal growth factor receptor 2 (HER2)-negative disease; 30% had HER2-positive disease; and 25% had triple-negative breast cancer (TNBC). There were 53% rural and 47% urban residents. In multivariate analysis for OS for stage 0 to IV disease, rural residence (hazard ratio [HR], 1.75 [95% CI, 1.08 to 2.81]), TNBC (HR, 2.25 [95% CI, 1.34 to 3.80]), and stage IV disease (HR, 8.1 [95% CI, 4.72 to 13.94]) were associated with inferior OS. CONCLUSION: AYA women with breast cancer have a high incidence of node-positive disease and aggressive subtypes. This study found a significant association between rural residence and OS. These findings emphasize the need for enhanced early detection and personalized treatment strategies, particularly for rural patients and those with TNBC.

  • Open Access

    Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach

    by Samitha Andrahennadi, Mita Manna

    Breast cancer remains the second leading cause of cancer-related death among women in Canada. In early-stage disease, the purpose of adjuvant therapies following surgical resection is to reduce the risk of recurrence. The advent of adjuvant endocrine therapy (ET) significantly reduced breast cancer recurrence and mortality; however, some patients have disease recurrence even 20 years after initial diagnosis. Therefore, several advancements have been made to optimize cure rates and improve outcomes. As a heterogeneous disease, breast cancer outcomes are impacted by clinical, histological, and genomic features, which guide prognosis and selection of adjuvant therapy. This review focuses on recent and emerging adjuvant therapies, specifically for high-risk patients across breast cancer subtypes: hormone receptor‑positive (HR‑positive), human epidermal growth factor receptor 2-positive (HER2-positive), and triple‑negative breast cancer (TNBC).